Income Statement Presentation 2023

Roche Group development pipeline Phase I (55 NMES + 12 Als) RG6007 HLA-A2-WT1 x CD3 AML RG6026 glofitamab monotherapy + combos RG6058 tiragolumab combos heme tumors heme & solid tumors RG6076 CD19-4-1BBL combos heme tumors RG7802 RG7827 RG7828 CHU cibisatamab + T solid tumors RG6026 glofitamab + chemo FAP-4-1BBL monotherapy + combos Lunsumio monotheraphy + combos glypican-3 x CD3 solid tumors tiragolumab + T heme tumors tiragolumab +T+chemo RG6058 solid tumors tiragolumab + T RG6129 HLA-A2-MAGE-A4 x CD3 solid tumors CHU codrituzumab HCC tiragolumab +T RG6160 RG6171 cevostamab (FcRH5 x CD3) giredestrant (SERD) r/r multiple myeloma CHU CD137 switch antibody solid tumors CHU RAS inhibitor solid tumors solid tumors RG6107 RG6139 crovalimab PD1 x LAG3 Phase II (23 NMES + 8 Als) Roche 1L ctDNA high risk DLBCL NSCLC NSCLC neoadj-adj cervical cancer 1L PD-L1+mSCCHN sickle cell disease solid tumors RG6114 RG6156 inavolisib (mPI3K alpha inh) EGFRvIII x CD3 solid tumors CHU SPYK04 solid tumors RG6180 autogene cevumeran + pembrolizumab glioblastoma SQZ PBMC vaccine solid tumors RG6354 zinpentraxin alfa (PRM-151) RG6180 autogene cevumeran + T solid tumors RG6287 IBD RG6357 SPK-8011 1L melanoma myelofibrosis hemophilia A RG6185 belvarafenib (pan-RAF inh) + Cotellic + T solid tumors RG6315 immunologic disorders RG6358 SPK-8016 hemophilia A with inhibitors to factor VIII RG6189 FAP-CD40 ±T solid tumors RG6341 RG6194 runimotamab (HER2 x CD3) BC RG6421 TMEM16A potentiator asthma cystic fibrosis RG6149 astegolimab (Anti-ST2) COPD RG62995 ASO factor B IgA nephropathy RG6234 forimtamig (GPRC5D x CD3) multiple myeloma RG65363 vixarelimab immunology RG6264 Phesgo OBI RG6279 PD1-IL2v + T RG6286 HER2+ BC solid tumors colorectal cancer RG7828 Lunsumio SLE CHU anti-HLA-DQ2.5 x gluten peptides celiac disease CHU RAY121 immunology RG7854/ RG6346/ RG6084** RG6359 RG1662 ruzotolimod (TLR7 ago[3])/ HBV xalnesiran (siRNA)/ PDL1 LNA SPK-3006 basmisanil Pompe disease Dup 15q syndrome RG6290 MAGE-A4 ImmTAC + T solid tumors RG6006 Abx MCP bacterial infections RG6042 tominersen Huntington's RG6292 CD25 MAb combos heme & solid tumors RG6319 LepB inhibitor complicated urinary tract infection RG6100 semorinemab RG6323 IL15/IL15Ra-Fc + T solid tumors RG6035 BS-CD20 MAb multiple sclerosis RG6102 RG6330 KRAS G12C solid tumors RG6091 rugonersen (UBE3A LNA) Angelman syndrome RG6237 RG6333 CD19 x CD28+ glofitamab RG6344 BRAF inhibitor (3) RG6392 RG6411 RG6433 SHP2i combos RG6440 TGFB (SOF 10) r/r NHL solid tumors oncology solid tumors solid tumors solid tumors RG6163 psychiatric disorders RG6416 trontinemab bepranemab Alzheimer's Alzheimer's latent myostatin + Evrysdi SMA Alzheimer's RG6512 FIXa x FX hemophilia RG6182 RG6237 RG6289 RG6418* RG7637 RG6120 RG6209 latent myostatin neurodegenerative diseases neuromuscular disorders RG7314 balovaptan post-traumatic stress disorder RG7412 crenezumab selnoflast Alzheimer's inflammation RG7816 alogabat (GABA Aa5 PAM) RG7906 ralmitaront - psychiatric disorders RG7935 prasinezumab VEGF-Ang2 DutaFab RG6524 solid tumors RG6312 RG65261 camonsertib solid tumors RG6351 RG65382 P-BCMA-ALLO1 multiple myeloma RG65014 OpRegen RG7446 RG7601 Morpheus platform solid tumors RG7921 Venclexta + azacitidine r/r MDS CHU anti-IL-8 recycling antibody Status as of February 2, 2023 RG-No - Roche/Genentech; CHU - Chugai managed; SQZ - SQZ Biotechnology managed; 'Repare Therapeutics managed; 2Poseida Therapeutics managed; ³Kiniksa Pharmaceuticals managed; 4Lineage Cell Therapeutics managed; 5IONIS managed; T-Tecentriq; BS=Brain Shuttle; OBI-On-Body Delivery System; *also developed in Immunology; **combination platform ASO factor B New Molecular Entity (NME) Oncology/Hematology Immunology Infectious Diseases nAMD retinal disease geographic atrophy retinal disease geographic atrophy RG6179 RG7774 RG62995 anti-IL-6 vicasinabin (CB2 receptor agonist) familial Alzheimer's healthy pts ASD schizophrenia Parkinson's DME DR RVO Additional Indication (Al) endometriosis geographic atrophy Metabolism Neuroscience Ophthalmology Other 77

View entire presentation